title: Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.
abstract: We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by two gray TBI non-myeloablative conditioning. All patients received a first HDT as frontline treatment. At day 100 post allo-SCT, complete donor chimerism was detected in 22 patients (95%). Acute GVHD was observed in 19 patients (15 grade I-II (65%) and 4 grade III-IV (17%)). Ten patients (43%) developed an extensive chronic GVHD. The non-relapse mortality at 1 year was 17%. After TT, the overall response rate was 91% (17% partial response, 35% very good partial remission and 39% complete remission). At 2 years, OS was 61%. Median event-free survival and OS were 36.8 and 60 months, respectively. Based on the propensity score matching method, a significant survival advantage could be seen in patients treated with TT as compared with non-allografted patients. Thus, allo-SCT, in TT approach, provides a high response rate with low toxicity and may improve survival of patients with relapsing MM.
authors.affiliation: Immuno-hematology Unit, Saint-Louis Hospital, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Karlin
authors.forename: B
authors.initials: B
authors.lastname: Arnulf
authors.forename: S
authors.initials: S
authors.lastname: Chevret
authors.forename: L
authors.initials: L
authors.lastname: Ades
authors.forename: M
authors.initials: M
authors.lastname: Robin
authors.forename: R P
authors.initials: RP
authors.lastname: De Latour
authors.forename: M
authors.initials: M
authors.lastname: Malphettes
authors.forename: N
authors.initials: N
authors.lastname: Kabbara
authors.forename: B
authors.initials: B
authors.lastname: Asli
authors.forename: V
authors.initials: V
authors.lastname: Rocha
authors.forename: J P
authors.initials: JP
authors.lastname: Fermand
authors.forename: G
authors.initials: G
authors.lastname: Socie
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000601:surgery*; D012008:Recurrence; D012189:Retrospective Studies; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous